Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.YARW · Entity 6871 | Director | July 27, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date July 27, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-07-27 | Direct | 185,798 |
Reported balance
After 2026-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 185,798 · Balance 185,798 F1: This option represents a right to purchase 185,798 shares of the Issuer's common stock, one quarter of which will vest on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 185,798 shares of the Issuer's common stock, one quarter of which will vest on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 30, 2026 01:33 UTC | Yarrow Bioscience, Inc. YARW · Entity 6871 | GrantStock Option (Right to Buy) · Derivative | 185,798 | $0.00 Strike: $28.56 | $0.00 |
DisclosureSEC source: 0001104659-26-088370 · tm2621459-10_4seq1.xml · derivative · entry 1 Zeronda Tyler · CIK 0001867033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,798 Underlying: Common Stock · 185,798 shares Expires 2036-07-27 F1 · derivative.exercise_date: This option represents a right to purchase 185,798 shares of the Issuer's common stock, one quarter of which will vest on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:00 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 22,516 | $0.90 | $20,210.36 |
DisclosureSEC source: 0001867033-26-000008 · form4-07242026_050707.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,918 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 00:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,464 | $0.65 | $2,254.02 |
DisclosureSEC source: 0001867033-26-000006 · form4-07022026_080706.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,434 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 4,007 | $0.60 | $2,394.18 |
DisclosureSEC source: 0001867033-26-000004 · form4-04022026_040408.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,788 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 13:30 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 7,858 | $0.58 | $4,558.43 |
DisclosureSEC source: 0001867033-26-000002 · form4-01052026_080105.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,795 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 21:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,420 | $0.34 | $1,145.70 |
DisclosureSEC source: 0001867033-25-000003 · form4-10022025_051007.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,653 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:30 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,420 | $1.65 | $5,643.00 |
DisclosureSEC source: 0001415889-25-019059 · form4-07022025_040710.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,073 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 8,399 | $1.58 | $13,270.42 |
DisclosureSEC source: 0001415889-25-009633 · form4-04022025_040416.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,493 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001415889-25-001927 · form4-01232025_040109.xml · derivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 22:45 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 4,675 | $3.35 | $15,661.25 |
DisclosureSEC source: 0001415889-25-000156 · form4-01022025_050107.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,892 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 84 | $1.88 | $157.92 |
DisclosureSEC source: 0001415889-24-024383 · form4-10022024_041008.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,567 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 92 | $1.92 | $176.64 |
DisclosureSEC source: 0001415889-24-019176 · form4-07032024_040715.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,651 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:08 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 94 | $3.08 | $289.52 |
DisclosureSEC source: 0001415889-24-010074 · form4-04032024_090450.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,743 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:22 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 93 | $2.28 | $212.04 |
DisclosureSEC source: 0001209191-24-000470 · doc4.xml · nonDerivative · entry 2 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,837 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:22 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000470 · doc4.xml · derivative · entry 3 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-12-31 F4 · derivative.exercise_date: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:22 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000470 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,930 F1 · shares: Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:11 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058819 · doc4.xml · derivative · entry 2 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-12-12 F3 · derivative.exercise_date: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:11 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058819 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,430 F1 · shares: Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:26 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,087 | $3.83 | $4,163.21 |
DisclosureSEC source: 0001209191-23-051960 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,930 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:37 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 91 | $4.10 | $373.10 |
DisclosureSEC source: 0001209191-23-041139 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,017 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:07 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 384 | $3.08 | $1,182.72 |
DisclosureSEC source: 0001209191-23-022806 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,108 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. F2 · balance_after: On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 354 | $0.15 | $53.10 |
DisclosureSEC source: 0001209191-23-001081 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,005 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 353 | $0.22 | $78.72 |
DisclosureSEC source: 0001209191-22-052359 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,359 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:01 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 354 | $0.39 | $137.71 |
DisclosureSEC source: 0001209191-22-040789 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,712 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:36 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 12,510 | $0.35 | $4,332.21 |
DisclosureSEC source: 0001209191-22-033544 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,066 F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2021 and ending on May 31, 2022 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2022 (the last trading day of the offering period). Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:10 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 773 | $0.65 | $502.45 |
DisclosureSEC source: 0001209191-22-022532 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,556 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 21:10 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 75,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-22-020067 · doc4.xml · derivative · entry 2 Zeronda Tyler · CIK 0001867033 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-03-17 F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2023 and 6.25% every three months thereafter, ending on March 31, 2026. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 21:10 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020067 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,329 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:40 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 206 | $1.02 | $210.12 |
DisclosureSEC source: 0001209191-22-000861 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,329 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:08 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 4,187 | $0.88 | $3,665.72 |
DisclosureSEC source: 0001209191-21-067649 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,535 F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2021 and ending on November 30, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2021 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 21:12 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 206 | $1.39 | $286.34 |
DisclosureSEC source: 0001209191-21-058522 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,348 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:35 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 60,860 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001209191-21-054837 · doc4.xml · derivative · entry 2 Zeronda Tyler · CIK 0001867033 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,860 Underlying: Common Stock · 60,860 shares Expires 2031-09-02 F2 · derivative.exercise_date: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:35 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 60,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054837 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,554 F1 · shares: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:37 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 700 | $3.51 | $2,457.00 |
DisclosureSEC source: 0001209191-21-044983 · doc4.xml · nonDerivative · entry 1 Zeronda Tyler · CIK 0001867033 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,695 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.